Rahima Jamal

5.2k total citations
33 papers, 408 citations indexed

About

Rahima Jamal is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rahima Jamal has authored 33 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rahima Jamal's work include Cancer Immunotherapy and Biomarkers (24 papers), Melanoma and MAPK Pathways (7 papers) and CAR-T cell therapy research (6 papers). Rahima Jamal is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Melanoma and MAPK Pathways (7 papers) and CAR-T cell therapy research (6 papers). Rahima Jamal collaborates with scholars based in Canada, United States and United Kingdom. Rahima Jamal's co-authors include Wilson H. Miller, Meriem Messaoudene, Karl Bélanger, Philip Wong, Bertrand Routy, Arielle Elkrief, Julie Malo, Nathalie Letarte, Wiam Belkaïd and Corentin Richard and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rahima Jamal

31 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rahima Jamal Canada	10	303	184	106	79	49	33	408
Jean David Fumet France	7	347 1.1×	87 0.5×	140 1.3×	85 1.1×	17 0.3×	14	409
François Audhuy United States	6	204 0.7×	93 0.5×	82 0.8×	61 0.8×	12 0.2×	8	310
Aurélie Lagrange France	9	267 0.9×	103 0.6×	157 1.5×	99 1.3×	17 0.3×	22	387
Ulf Forssmann Germany	11	152 0.5×	189 1.0×	207 2.0×	56 0.7×	18 0.4×	24	409
Aditi Kothari United States	5	346 1.1×	237 1.3×	258 2.4×	58 0.7×	44 0.9×	10	523
Iris Mimpen United States	3	372 1.2×	309 1.7×	211 2.0×	72 0.9×	58 1.2×	3	611
Clara Chong Hui Ong Singapore	11	281 0.9×	162 0.9×	204 1.9×	64 0.8×	28 0.6×	19	498
Norbert Wiedemann Switzerland	9	118 0.4×	252 1.4×	63 0.6×	25 0.3×	21 0.4×	15	347
Sarah Mills United Kingdom	8	313 1.0×	91 0.5×	165 1.6×	64 0.8×	33 0.7×	15	451
Xi‐Zhao Li China	11	159 0.5×	133 0.7×	31 0.3×	45 0.6×	28 0.6×	26	320

Countries citing papers authored by Rahima Jamal

Since Specialization

Citations

This map shows the geographic impact of Rahima Jamal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rahima Jamal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rahima Jamal more than expected).

Fields of papers citing papers by Rahima Jamal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rahima Jamal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rahima Jamal. The network helps show where Rahima Jamal may publish in the future.

Co-authorship network of co-authors of Rahima Jamal

This figure shows the co-authorship network connecting the top 25 collaborators of Rahima Jamal. A scholar is included among the top collaborators of Rahima Jamal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rahima Jamal. Rahima Jamal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baines, Kelly J., Wilson H. Miller, Rahima Jamal, et al.. (2025). Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. Journal for ImmunoTherapy of Cancer. 13(8). e012659–e012659. 2 indexed citations

Wang, Judy S., Edward Arrowsmith, J. Thaddeus Beck, et al.. (2025). Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors. Investigational New Drugs. 43(4). 894–903. 1 indexed citations

Berthiaume, Luc G., Erwan Beauchamp, Morris A. Kostiuk, et al.. (2024). Abstract CT194: N-myristoylation inhibitor zelenirstat: New mechanistic insights and efficacy signals from a first in human phase I study. Cancer Research. 84(7_Supplement). CT194–CT194. 1 indexed citations

Sangha, Randeep, Rahima Jamal, Jennifer L. Spratlin, et al.. (2024). A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Investigational New Drugs. 42(4). 386–393. 7 indexed citations

Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2024). Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.. Journal of Clinical Oncology. 42(16_suppl). 9559–9559. 1 indexed citations

Bahig, Houda, F. Aubin, Phuc Félix Nguyen‐Tan, et al.. (2023). Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.. Journal of Clinical Oncology. 41(16_suppl). 6050–6050. 1 indexed citations

Sebajang, Herawaty, et al.. (2023). Primary malignant melanoma of the vagina: A case report. Gynecologic Oncology Reports. 49. 101266–101266. 2 indexed citations

Jamal, Rahima, et al.. (2023). Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. Seminars in Immunology. 67. 101754–101754. 16 indexed citations

Fu, Siqing, Udai Banerji, Philippe L. Bédard, et al.. (2022). Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies. Cancer Research. 82(12_Supplement). CT503–CT503. 6 indexed citations

10.

Bahig, Houda, F. Aubin, Phuc Félix Nguyen‐Tan, et al.. (2020). Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.. Journal of Clinical Oncology. 38(15_suppl). 6531–6531. 5 indexed citations

11.

Machado, Marina Amaral de Ávila, Cristiano Soares de Moura, Kelvin Chan, et al.. (2020). Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Scientific Reports. 10(1). 14607–14607. 9 indexed citations

12.

Bahig, Houda, F. Aubin, John Stagg, et al.. (2019). Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer. 19(1). 68–68. 40 indexed citations

13.

Elkrief, Arielle, Corentin Richard, Meriem Messaoudene, et al.. (2019). Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. OncoImmunology. 8(4). e1568812–e1568812. 152 indexed citations

14.

Hollebecque, Antoine, Zev A. Wainberg, Jaffer A. Ajani, et al.. (2018). Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology. 36(15_suppl). 4032–4032. 5 indexed citations

15.

Miller, Wilson H., Rahima Jamal, Eftihia Cocolakis, et al.. (2018). Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. Journal of Clinical Oncology. 36(5_suppl). 185–185. 1 indexed citations

16.

Jamal, Rahima, Réjean Lapointe, Eftihia Cocolakis, et al.. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for ImmunoTherapy of Cancer. 5(1). 83–83. 38 indexed citations

17.

Antonia, Scott, Julie R. Brahmer, Ani Sarkis Balmanoukian, et al.. (2017). Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. Journal of Clinical Oncology. 35(15_suppl). e20504–e20504. 8 indexed citations

18.

Jamal, Rahima, Karl Bélanger, Jennifer Friedmann, et al.. (2014). A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology. 32(15_suppl). 9066–9066. 7 indexed citations

19.

Goodwin, Rachel, Rahima Jamal, Dongsheng Tu, et al.. (2013). Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology. 131(2). 315–320. 10 indexed citations

20.

Assouline, Sarit, Eftihia Cocolakis, Abdellatif Amri, et al.. (2011). A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,. Blood. 118(21). 3606–3606. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact